Gsk Share Discussion Threads

[zicopele] 18/3/2020 16:40

Depreciation of Stg will provide some support.

Expecting fall in dividend.

[mister md] 18/3/2020 14:21

would have expected GSK to be a bit more resilient to the market sell off

[abdullla] 18/3/2020 13:08

Unlike India or Japan Big pharmas are not talking any chances which could backfire.

[abdullla] 18/3/2020 13:03

TM i think reading between the lines it answers my question,I hope the experts sort this mess out sooner than latter.

[abdullla] 18/3/2020 12:16

Some companies have cancelled their forthcoming dividend,is there any chance GSK could do the same ???

[tradermichael] 17/3/2020 16:50

Over 22 million GSK shares traded today

GBP 1.0 = USD 1.20, good for income

[alphorn] 17/3/2020 12:40

Der US-Pharmakonzern Pfizer arbeitet mit der Mainzer Biotech-Firma BioNtech SE an der Entwicklung eines Coronavirus-Impfstoffs. They collaborated from 2018.

[crossing_the_rubicon] 17/3/2020 12:29

Regeneron reported that tests for its "antibody-based" remedies for the coronavirus infection could be ready for the final round of clinical testing by the beginning of the summer, which could see a drug shipped by the end of the summer, according to CNBC's Meg Tirrell.

Pfizer, meanwhile, announced it would partner with a Swiss biotech company to produce a vaccine using a technology similar to Moderna.

Reporting from Beijing, CNBC's Eunice Yoon, reported that a Chinese trial for favipiravir, another antiviral designed to treat the virus, showed "promising" results.

[crossing_the_rubicon] 17/3/2020 11:24

A potential COVID-19 vaccine from Moderna (NASDAQ:MRNA) has moved into human testing, with the first participant receiving treatment on Monday. A total of 45 healthy adults will receive one of three dose levels (25, 100, 250 µg) of the candidate, called mRNA-1273, and will be followed for 12 months after receiving the second vaccination. The primary endpoint is safety, including reactogenicity (the expected adverse events such as excessive immunological responses and injection site reactions). The secondary endpoint is immunogenicity (the robustness of the immune response).

[tradermichael] 17/3/2020 08:18

GBP 1.00 = USD 1.22

[tradermichael] 17/3/2020 08:14

PramBigear - Exactly! …. ;0)

[bilster1] 17/3/2020 07:56

Hi Monty - what news is the that?

[montyhedge] 16/3/2020 21:15

Seen the article several newspapers, could be massive if it works for GSK.

[crossing_the_rubicon] 16/3/2020 19:09

Health Canada has approved the use of GlaxoSmithKline's (GSK -9.6%) Nucala (mepolizumab) in children as young as six years old with severe eosinophilic asthma. The previous age limit was 12 years.

[prambigear] 16/3/2020 17:11

#20918 Erm. The soldiers travelled HOME, to a population that on the whole didn't travel and were more rural.

[tradermichael] 16/3/2020 16:55

Zai Lab Ltd. said the China National Medical Products Administration accepted its supplemental new drug application for Zejula as a maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

The company said the Prima study, conducted by partner GlaxoSmithKline PLC, demonstrated Zejula treatment resulted in a 38% reduction in the risk of disease progression or death in the overall study population when compared to placebo. Zejula demonstrated benefits in all patient subgroups, the company said.

For patients whose cancer is associated with homologous recombination deficiency positive status, Zejula treatment resulted in a 57% reduction in the risk of disease progression or death, Zai Lab said.

GSK submitted a sNDA to the U.S. Food and Drug Administration for the use of Zejula in ovarian cancer as first-line maintenance treatment and the application was accepted in February.

[bc4] 16/3/2020 13:36

Some people think they know it all but know very little eh PORSCHE


Porsche1945

12 Mar '20 - 10:08 - 20885 of 20920

Back in at 1447 to start building a position, I love this share, one of the best for trading I have ever owned, will be serious money to be made on the bounce, the whole thing over hyped and juiced by social media, will soon get boring and markets in general and Gsk in particular will bounce. Its times like this you make real money, as long as you have the funds or Lombard margin.

[porsche1945] 16/3/2020 13:03

This isnt Spanish flu or anything like it, virologists say it actually has a kill rate of 0.7 pc, less than normal flu. Completely overhyped, looking forward to buying more of what I like ever cheaper for a nice profit on the bounce.

[crossing_the_rubicon] 16/3/2020 11:32

@Abdulla.

Indeed, see Cineworld!
See Mars. See TLW/PMO

See Shell.

Simply wow,wow, gobsmacked.

[tradermichael] 16/3/2020 11:31

Erm, it did, in fact, spread very widely. People did travel (millions of troops worldwide) and this facilitated the spread.

The Spanish flu infected 500 million people around the world, or about 27% of the then world population of between 1.8 and 1.9 billion, including people on isolated Pacific islands and in the Arctic.

Also, you state that it 'came back' at least twice. But this wasn't due to lack of herd immunity, its because it mutated:

The second wave of the 1918 pandemic was much deadlier than the first. The first wave had resembled typical flu epidemics; those most at risk were the sick and elderly, while younger, healthier people recovered easily. By August, when the second wave began in France, Sierra Leone, and the United States, the virus had mutated to a much deadlier form. October 1918 was the deadliest month of the whole pandemic.

[prambigear] 16/3/2020 11:14

#20911 Correct, and a good example for the government's advisors. People didn't travel then on the whole. Therefore it didn't spread very widely. So no 'herd immunity', it came back, at least twice.

[abdullla] 16/3/2020 10:51

You forgot the WOWs for the other stocks which are sadly near to suicidal stages

[crossing_the_rubicon] 16/3/2020 10:17

Wow simply wow at the current share price.